Sarepta Therapeutics, Inc.
SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exonā¦ read more
Healthcare
Biotechnology
28 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$21.66
Price-2.43%
-$0.54
1Y
Price
Market Cap
$2.122b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-45.5%
EBITDA Margin-45.1%
Net Profit Margin-
Free Cash Flow MarginRevenue
$2.414b
+26.9%
1y CAGR+37.7%
3y CAGR+36.5%
5y CAGREarnings
-$271.514m
-215.4%
1y CAGR-15.9%
3y CAGR-28.9%
5y CAGREPS
-$3.01
-228.6%
1y CAGR-20.2%
3y CAGR-29.1%
5y CAGRBook Value
$1.320b
$3.493b
Assets$2.173b
Liabilities$1.260b
DebtDebt to Assets
36.1%
-6.5x
Debt to EBITDAFree Cash Flow
-$343.583m
-0.2%
1y CAGR-7.7%
3y CAGR+0.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company